Recombinant CD19 (Tafasitamab Biosimilar) anticorps

N° du produit ABIN7488054

Cet anticorps Mammalian Cells Monoclonal détecte spécifiquement CD19 (Tafasitamab Biosimilar) dans ELISA. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant CD19 (Tafasitamab Biosimilar) anticorps (ABIN7488054)

Antigène: CD19 (Tafasitamab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp CD19 (Tafasitamab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-CD19 (Tafasitamab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Tafasitamab Biosimilar - Anti-CD19 mAb

Attributs du produit: Antibody Type: IgG1-G2-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: -80 °C

Stockage commentaire: store at -80°C

Détails sur CD19 (Tafasitamab Biosimilar)

Antigène: CD19 (Tafasitamab Biosimilar)

Classe de substances: Biosimilar

Sujet: MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19
Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells.

Numéro CAS: 1422527-84-1